Cytokines and their role in cardiovascular diseases

Vasan, 2006, Biomarkers of cardiovascular disease, Circulation, 113, 2335, 10.1161/CIRCULATIONAHA.104.482570 A.A. Justiz Vaillant, A. Qurie, Interleukin. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC., 2022. Battistoni, 2012, Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases, Int. J. Cardiol., 157, 160, 10.1016/j.ijcard.2011.06.066 M. Akdis, S. Burgler, R. Crameri, T. Eiwegger, H. Fujita, E. Gomez, et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases, J. Allergy Clin. Immunol. 127(3)(2011):701-21.e1-70. Jiang, 2019, Inflammasome-driven interleukin-1α and interleukin-1β production in atherosclerotic plaques relates to hyperlipidemia and plaque complexity. JACC: Basic to Translational, Science, 4, 304 Silvain, 2020, Interleukin-1β and risk of premature death in patients with myocardial infarction, J. Am. Coll. Cardiol., 76, 1763, 10.1016/j.jacc.2020.08.026 Li, 2019, IL (Interleukin)-33 suppresses abdominal aortic aneurysm by enhancing regulatory T-cell expansion and activity, Arterioscler. Thromb. Vasc. Biol., 39, 446, 10.1161/ATVBAHA.118.312023 Demyanets, 2011, Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques, Arterioscler. Thromb. Vasc. Biol., 31, 2080, 10.1161/ATVBAHA.111.231431 Sugano, 2017, Abstract 21000: Interaction Between Mineralocorticoid Receptor Antagonist and Soluble ST2 in Heart Failure With Preserved Ejection Fraction, Circulation, 136(suppl_1):A21000-A Bayés-Genis, 2018, ST2 in heart failure: the lungs claim their contribution, Am Heart Assoc, e005582 Ghali, 2018, IL-33 (interleukin 33)/sST2 axis in hypertension and heart failure, Hypertension, 72, 818, 10.1161/HYPERTENSIONAHA.118.11157 Seki, 2009, Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circulation, Heart Failure., 2, 684, 10.1161/CIRCHEARTFAILURE.109.873240 Tiret, 2005, Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease, Circulation, 112, 643, 10.1161/CIRCULATIONAHA.104.519702 Mallat, 2004, Evidence for altered interleukin (IL)-18 pathway in human heart failure, FASEB J., 18, 1752, 10.1096/fj.04-2426fje White, 2006, Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support, Clin. Sci., 110, 483, 10.1042/CS20050317 Blankenberg, 2002, Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina, Circulation, 106, 24, 10.1161/01.CIR.0000020546.30940.92 Chia, 2021, Interleukin 6 and development of heart failure with preserved ejection fraction in the general population, J. Am. Heart Assoc., 10, e018549, 10.1161/JAHA.120.018549 Vasques-Nóvoa, 2022, Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry, Cytokine, 160, 10.1016/j.cyto.2022.156053 Ferencik, 2022 Maeda, 2006, Abstract 1123: Interleukin (IL)-11 Prevents Ischemia/Reperfusion Injury in Hearts as a Novel Cardioprotective Cytokine, Circulation, 114(suppl_18):II_208-II_ Gokkusu, 2010, Influences of genetic variants in interleukin-15 gene and serum interleukin-15 levels on coronary heart disease, Cytokine, 49, 58, 10.1016/j.cyto.2009.09.004 Borowiec, 2015, Prospective assessment of cytokine IL-15 activity in patients with refractory atrial fibrillation episodes, Cytokine, 74, 164, 10.1016/j.cyto.2015.04.002 Ameri, 2020, Administration of interleukin-15 peptide improves cardiac function in a mouse model of myocardial infarction, J. Cardiovasc. Pharmacol., 75, 98, 10.1097/FJC.0000000000000764 Mallat, 1999, Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death, Arterioscler. Thromb. Vasc. Biol., 19, 611, 10.1161/01.ATV.19.3.611 Potteaux, 2004, Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice, Arterioscler. Thromb. Vasc. Biol., 24, 1474, 10.1161/01.ATV.0000134378.86443.cd Ellison, 2013, Attenuation of experimental atherosclerosis by interleukin-19, Arterioscler. Thromb. Vasc. Biol., 33, 2316, 10.1161/ATVBAHA.113.301521 Chen, 2006, IL-20 Is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E–deficient mice, Arterioscler. Thromb. Vasc. Biol., 26, 2090, 10.1161/01.ATV.0000232502.88144.6f Zhang, 2021, Increased expression of IL-20 is associated with ischemic cardiomyopathy and acute myocardial infarction, Biomark. Med., 15, 1641, 10.2217/bmm-2020-0529 Gangemi, 2010, Is interleukin-22 a possible indicator of chronic heart failure's progression?, Arch. Gerontol. Geriatr., 50, 311, 10.1016/j.archger.2009.05.003 Wu, 2016, Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation, Sci. Rep., 6, 1 Xia, 2012, Characterisation of IL-22 and interferon-gamma-inducible chemokines in human carotid plaque, Int. J. Cardiol., 154, 187, 10.1016/j.ijcard.2011.10.093 Ye, 2017, Interleukin 22 promotes blood pressure elevation and endothelial dysfunction in angiotensin II–treated mice, J. Am. Heart Assoc., 6, e005875, 10.1161/JAHA.117.005875 Kong, 2013, IL-22 exacerbates the severity of CVB3-induced acute viral myocarditis in IL-17A-deficient mice, Mol. Med. Rep., 7, 1329, 10.3892/mmr.2013.1323 Lee, 2012, Interleukin-24 attenuates β-glycerophosphate-induced calcification of vascular smooth muscle cells by inhibiting apoptosis, the expression of calcification and osteoblastic markers, and the Wnt/β-catenin pathway, Biochem. Biophys. Res. Commun., 428, 50, 10.1016/j.bbrc.2012.09.145 Vargas-Alarcón, 2014, IL-24 gene polymorphisms are associated with cardiometabolic parameters and cardiovascular risk factors but not with premature coronary artery disease: the genetics of atherosclerotic disease Mexican study, J. Interferon Cytokine Res., 34, 659, 10.1089/jir.2013.0081 Yong, 2013, Interleukin-12 is associated with arterial stiffness in healthy individuals, Am. J. Hypertens., 26, 159, 10.1093/ajh/hps032 Christensen, 2019, Increased Th-1 Cytokine Response in Patients With Coronary Microvascular Dysfunction, Arterioscler. Thromb. Vasc. Biol., 39(Suppl_1):A348-A Zhou, 2001, Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population, J. Atheroscler. Thromb., 8, 30, 10.5551/jat1994.8.30 Abbas, 2015, Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis, Stroke, 46, 793, 10.1161/STROKEAHA.114.006516 Qiu, 2016, Interleukin-27 enhances TNF-α-mediated activation of human coronary artery endothelial cells, Mol. Cell. Biochem., 411, 1, 10.1007/s11010-015-2563-3 Lin, 2012, Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases, PLoS One, 7, e52490, 10.1371/journal.pone.0052490 Rus, 1996, Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall, Atherosclerosis, 127, 263, 10.1016/S0021-9150(96)05968-0 Apostolopoulos, 1996, Interleukin-8 production by macrophages from atheromatous plaques, Arterioscler. Thromb. Vasc. Biol., 16, 1007, 10.1161/01.ATV.16.8.1007 Amir, 2012, Changes in the monocytic subsets CD14dimCD16+ and CD14++ CD16− in chronic systolic heart failure patients, Mediators Inflamm., 2012, 10.1155/2012/616384 Jafarzadeh, 2009, Serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease, Anatolian Journal of Cardiology/Anadolu Kardiyoloji Dergisi., 9 Sicklinger, 2021, Basophils balance healing after myocardial infarction via IL-4/IL-13, J. Clin. Investig., 131, e136778, 10.1172/JCI136778 O’Meara, 2017, Interleukin 13 is Required for Neonatal Heart Regeneration, Circ. Res., 121(suppl_1):A348-A Brånén, 2004, Inhibition of Tumor Necrosis Factor-α Reduces Atherosclerosis in Apolipoprotein E Knockout Mice, Arterioscler. Thromb. Vasc. Biol., 24, 2137, 10.1161/01.ATV.0000143933.20616.1b Josephs, 2018, Unleashing endogenous TNF-alpha as a cancer immunotherapeutic, J. Transl. Med., 16, 242, 10.1186/s12967-018-1611-7 Sriramula S, Mariappan N, McILwain E, Francis J. Abstract 1476: Angiotensin II Induced Hypertrophic Response And Oxidative Stress Is Attenuated In Mice Lacking The Gene For Tnf-α. Circulation. 2007;116(suppl_16):II_304-II_. Irwin, 1999, Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium, Circulation, 99, 1492, 10.1161/01.CIR.99.11.1492 Chen, 2020, Type-I interferons in atherosclerosis, J Exp Med., 217, 10.1084/jem.20190459 Ding, 2020, IFN-I Mediates Dysfunction of Endothelial Progenitor Cells in Atherosclerosis of Systemic Lupus Erythematosus, Front Immunol., 11, 10.3389/fimmu.2020.581385 Teixeira, 2005, The role of interferon-gamma on immune and allergic responses, Mem. Inst. Oswaldo Cruz, 100, 137, 10.1590/S0074-02762005000900024 Elyasi, 2020, The role of interferon-γ in cardiovascular disease: an update, Inflamm Res., 69, 975, 10.1007/s00011-020-01382-6 Ketelhuth, 2011, Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall, Thromb Haemost., 106, 779, 10.1160/TH11-05-0321 Voloshyna, 2014, Atherosclerosis and interferon-γ: new insights and therapeutic targets, Trends Cardiovasc Med., 24, 45, 10.1016/j.tcm.2013.06.003 Weber, 2010, Interleukin-1 (IL-1) pathway, Sci. Signal., 3(105):cm1-cm Zhao, 2019, Targeting the immune system in atherosclerosis: JACC state-of-the-art review, J. Am. Coll. Cardiol., 73, 1691, 10.1016/j.jacc.2018.12.083 Wæhre, 2004, Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors, Circulation, 109, 1966, 10.1161/01.CIR.0000125700.33637.B1 Pascual-Figal, 2019, The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure, J. Am. Coll. Cardiol., 73, 1016, 10.1016/j.jacc.2018.11.054 Everett, 2020, Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial, J. Am. Coll. Cardiol., 76, 1660, 10.1016/j.jacc.2020.08.011 Sánchez-Más, 2014, Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers, Eur J Clin Invest., 44, 643, 10.1111/eci.12282 Legere SA, Marshall JS, Légaré J-F. Local Production of Interleukin-33 and its Ability to Activate Mast Cells to Produce Pro-fibrotic Mediators May be Associated With Cardiac Fibrosis. Circulation. 2016;134(suppl_1):A16932-A. Sawada, 2012, Interleukin-33 and Soluble ST2 Are Expressed in Human Nonrheumatic Aortic Valve Stenosis, Am Heart Assoc Yamagami, 2005, Associations of serum IL-18 levels with carotid intima-media thickness, Arterioscler. Thromb. Vasc. Biol., 25, 1458, 10.1161/01.ATV.0000168417.52486.56 Blankenberg, 2002, Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina, Circulation, 106, 24, 10.1161/01.CIR.0000020546.30940.92 Jenny, 2002, In the elderly, interleukin-6 plasma levels and the− 174G> C polymorphism are associated with the development of cardiovascular disease, Arterioscler. Thromb. Vasc. Biol., 22, 2066, 10.1161/01.ATV.0000040224.49362.60 Jia X, Buckley L, Sun C, Rifai MA, Yu B, NAMBI V, et al. Abstract 11125: Association of Interleukin-6 and Interleukin-18 With Global Cardiovascular Disease in Older Adults. Circulation. 2022;146(Suppl_1):A11125-A. Zegeye, 2021, IL-6 as a Mediator of the Association Between Traditional Risk Factors and Future Myocardial Infarction, Arterioscler. Thromb. Vasc. Biol., 41, 1570, 10.1161/ATVBAHA.120.315793 Kimura, 2007, Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine, Cytokine, 38, 107, 10.1016/j.cyto.2007.05.011 Harhous, 2019, An Update on the Multifaceted Roles of STAT3 in the Heart, Front Cardiovasc Med., 6, 150, 10.3389/fcvm.2019.00150 Pipicz, 2018, Effects of cardiovascular risk factors on cardiac STAT3, Int. J. Mol. Sci., 19, 3572, 10.3390/ijms19113572 Podewski, 2003, Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy, Circulation, 107, 798, 10.1161/01.CIR.0000057545.82749.FF Tamura, 2018, The cardioprotective effect of interleukin-11 against ischemia-reperfusion injury in a heart donor model, Annals of Cardiothoracic Surgery., 7, 99, 10.21037/acs.2017.09.11 Yeghiazarians, 2014, IL-15: A novel pro-survival signaling pathway in cardiomyocytes, J. Cardiovasc. Pharmacol., 63, 406, 10.1097/FJC.0000000000000061 Zhou, 2000, Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology, American Journal of Physiology-Heart and Circulatory Physiology., 279, H429, 10.1152/ajpheart.2000.279.1.H429 Shinozaki, 2002, IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis, J. Clin. Invest., 109, 951, 10.1172/JCI0214574 Hanisch, 1997, Mouse brain microglia express interleukin-15 and its multimeric receptor complex functionally coupled to Janus kinase activity, J. Biol. Chem., 272, 28853, 10.1074/jbc.272.46.28853 Stumpf, 2003, Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure, Clin. Sci., 105, 45, 10.1042/CS20020359 Lakoski, 2008, Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study, Atherosclerosis, 197, 443, 10.1016/j.atherosclerosis.2007.06.033 Welsh, 2011, Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk, Arterioscler. Thromb. Vasc. Biol., 31, 2338, 10.1161/ATVBAHA.111.231795 Autieri, 2018, IL-19 and other IL-20 family member cytokines in vascular inflammatory diseases, Front. Immunol., 9, 700, 10.3389/fimmu.2018.00700 Chen, 2021, The role and transformative potential of IL-19 in atherosclerosis, Cytokine Growth Factor Rev., 62, 70, 10.1016/j.cytogfr.2021.09.001 Zhang, 2020, The expression of interleukin 20 increases in plasma and aortic tissues from patients with acute aortic dissection, Clin. Chim. Acta, 510, 373, 10.1016/j.cca.2020.07.049 Ye, 2019, Increased Interleukin-11 Levels Are Correlated with Cardiac Events in Patients with Chronic Heart Failure, Mediators Inflamm., 2019, 1575410, 10.1155/2019/1575410 Guo, 2014, IL-22-producing Th22 cells play a protective role in CVB3-induced chronic myocarditis and dilated cardiomyopathy by inhibiting myocardial fibrosis, Virol J., 11, 230, 10.1186/s12985-014-0230-z Lee, 2013, Differential gene expression profiles in spontaneously hypertensive rats induced by administration of enalapril and nifedipine, Int. J. Mol. Med., 31, 179, 10.3892/ijmm.2012.1183 Yong, 2013, Elevated interleukin-12 and interleukin-18 in chronic kidney disease are not associated with arterial stiffness, Cytokine, 64, 39, 10.1016/j.cyto.2013.05.023 Li, 2018, Protection from psoriasis-related thrombosis after inhibition of IL-23 or IL-17A, J, Invest. Dermatol., 138, 310, 10.1016/j.jid.2017.09.021 Jin, 2012, Elevated circulating interleukin-27 in patients with coronary artery disease is associated with dendritic cells, oxidized low-density lipoprotein, and severity of coronary artery stenosis, Mediators Inflamm., 2012, 10.1155/2012/506283 Ganguly, 2018, Do Type I Interferons Link Systemic Autoimmunities and Metabolic Syndrome in a Pathogenetic Continuum?, Trends Immunol., 39, 28, 10.1016/j.it.2017.07.001 Niessner, 2006, Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha, Circulation, 114, 2482, 10.1161/CIRCULATIONAHA.106.642801 Guarda, 2011, Type I interferon inhibits interleukin-1 production and inflammasome activation, Immunity, 34, 213, 10.1016/j.immuni.2011.02.006 González-Navajas, 2012, Immunomodulatory functions of type I interferons, Nat Rev Immunol., 12, 125, 10.1038/nri3133 Engelbertsen, 2013, T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke, Arterioscler Thromb Vasc Biol., 33, 637, 10.1161/ATVBAHA.112.300871 Nagano, 1997, Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts, J Clin Invest., 100, 550, 10.1172/JCI119564 Whitman, 2000, Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice, Am J Pathol., 157, 1819, 10.1016/S0002-9440(10)64820-1 Moss, 2015, Interferon-γ: Promising therapeutic target in atherosclerosis, World J. Exp. Med., 5, 154, 10.5493/wjem.v5.i3.154 Silvennoinen, 1993, Interferon-induced nuclear signalling by Jak protein tyrosine kinases, Nature, 366, 583, 10.1038/366583a0 Hastings, 2009, Human IL-8 regulates smooth muscle cell VCAM-1 expression in response to endothelial cells exposed to atheroprone flow, Arterioscler. Thromb. Vasc. Biol., 29, 725, 10.1161/ATVBAHA.109.184382 Xing, 2012, Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury, Circulation, 125, 1533, 10.1161/CIRCULATIONAHA.111.078436 Nishimura, 2009, Increased interleukin-13 levels in patients with chronic heart failure, Int. J. Cardiol., 131, 421, 10.1016/j.ijcard.2007.07.128 Yuan, 2018, HDAC11 regulates interleukin-13 expression in CD4+ T cells in the heart, J. Mol. Cell. Cardiol., 122, 1, 10.1016/j.yjmcc.2018.07.253 Legere, 2016, Abstract 16932: Local Production of Interleukin-33 and its Ability to Activate Mast Cells to Produce Pro-fibrotic Mediators May be Associated With Cardiac Fibrosis, Circulation, 134(suppl_1):A16932-A Castiglione, 2022, Biomarkers for the diagnosis and management of heart failure, Heart Fail. Rev., 27, 625, 10.1007/s10741-021-10105-w